Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Next Previous
Trial Profile

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary) ; Navepegritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms COACH
  • Sponsors Ascendis Pharma

Most Recent Events

  • 09 Jun 2025 According to an Ascendis Pharma media release, Ascendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss these results. This interim analysis (week 26) will be followed by Week 52 data, expected in Q4 2025
  • 09 Jun 2025 Week 26 interim analysis results from this ongoing COACH Trial presented in the Ascendis Pharma Media Release
  • 01 May 2025 According to an Ascendis Pharma media release, the company expects topline Week 26 data from this study in Q2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top